Business Wire

Celltrion Healthcare receives EU CHMP positive opinion for biosimilar adalimumab, CT-P17

Share

Celltrion Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorisation of an adalimumab biosimilar candidate referencing Humira®1, CT-P17 recommending approval for all available indications.

The CHMP positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU). The EC’s decision regarding approval is expected in the first quarter of 2021, which would broaden treatment alternatives for patients suffering from rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), axial spondyloarthritis (AS), psoriatic arthritis (PsA), psoriasis (Ps), paediatric plaque psoriasis (pPs), hidradenitis suppurativa (HS), Crohn’s disease (CD), paediatric Crohn’s disease (pCD), ulcerative colitis (UC), uveitis (UV) and paediatric uveitis (pUV).

“If CT-P17 receives approval by the EC, Celltrion will be the first company to introduce an adalimumab biosimilar with high concentration and citrate-free formulation,” said HoUng Kim, Head of Medical and Marketing Division at Celltrion Healthcare. “This portfolio expansion is in line with our mission to improve access to biologics. We aim to provide a wide range of anti-TNF treatment alternatives, together with Remsima® dual formulation in IV formulation and SC formulation, for patients suffering from chronic inflammatory diseases.”

This positive opinion is based on the phase I/III studies to evaluate pharmacokinetics (PK), efficacy and safety between CT-P17 and reference adalimumab.2,3 The clinical data support the conclusion of biosimilarity of the proposed biosimilar and adalimumab to the reference product in terms of safety, efficacy, PK/PD and immunogenicity.

A randomised, double-blind phase III study in RA patients demonstrating similarity in terms of efficacy, pharmacokinetics (PK) and safety, including immunogenicity up to 24 weeks was presented at the ACR Convergence 2020.4 CT-P17 met the primary objective of demonstrating equivalent efficacy and its safety profile was comparable to that of reference adalimumab.

Further, a randomised, double-blind, single-dose study phase I study demonstrated PK and safety equivalence of CT-P17 in comparison to EU-approved adalimumab (EU - adalimumab) and US- licensed adalimumab (US - adalimumab) in healthy subjects up to 10 weeks. The overall safety profile was comparable, and the number of subjects who had positive ADA and neutralising ADA (NAb) results were also similar among the three treatment groups.2

Professor Edward Keystone, Senior Consultant Rheumatologist, Mount Sinai Hospital, Toronto, Canada said, “The CHMP positive opinion is very encouraging as CT-P17 has demonstrated promising study results in efficacy, PK and safety profile compared to reference adalimumab. Also having a high-concentration and citrate-free formulation would provide patients less pain during administration leading to improved quality of life.”

The EC takes binding decisions on the authorisation of medicines valid throughout the EU. It bases its decisions on scientific assessments by the CHMP, ensuring that medicines comply with high quality, safety and efficacy standards. If approved, the EC will grant a centralised marketing authorisation valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway.

- ENDS -

Notes to Editors:

About CT-P17 (biosimilar adalimumab)

CT-P17 is the first proposed high-concentration adalimumab biosimilar. If granted authorisation, CT-P17 will be indicated for the treatment of patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), axial spondyloarthritis (AS), psoriatic arthritis (PsA), psoriasis (Ps), paediatric plaque psoriasis (pPs), hidradenitis suppurativa (HS), Crohn’s disease (CD), paediatric Crohn’s disease (pCD), ulcerative colitis (UC), uveitis (UV) and paediatric uveitis (pUV). CT-P17 is a recombinant human monoclonal antibody that contains the active ingredient adalimumab. Adalimumab is a fully human anti–tumour necrosis factor α (anti-TNFα) monoclonal antibody. CT-P17 provides pain-reducing features as it comes with citrate-free formulation, meaning it causes less pain upon injection.

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 120 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us

Forward Looking Statement

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion/Celltrion Healthcare that may constitute forward-looking statements, under pertinent securities laws.

These statements may be identified by words such as “prepares”, “hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”, “is preparing, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion/Celltrion Healthcare's management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of Celltrion/Celltrion Healthcare believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion/Celltrion Healthcare undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

References


1 Humira is a registered trademark of AbbVie Biotechnology Ltd

2 Yu KS, et al. (2020). Pharmacokinetics and Safety of CT-P17, a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar, in Comparison with EU-Approved Adalimumab and US-Licensed Adalimumab; Results of a Phase 1, Randomized, Double-blind, Three-arm, Single-dose Study in Healthy Subjects. Poster Presented at ACR Convergence 2020

3 National Library of Medicine (US). 2018 November - . A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis. Identifier NCT03789292. Available from: https://clinicaltrials.gov/ct2/show/study/NCT03789292

4 J. Kay., et al. (2020). A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar (CT-P17) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis. Poster Presented at ACR Convergence 2020

Contact information

Zuzanna Grzeskiewicz
zgrzeskiewicz@hanovercoms.com
+44 (0)7596 339043

Sophia Eminson
seminson@hanovercomms.com
+44 (0) 7751 116252

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Esri Launches ArcGIS Platform27.1.2021 17:00:00 CETPress release

Esri, the global leader in location intelligence, today announced the launch of ArcGIS Platform, a geospatial platform as a service (PaaS) for developers that need to integrate location capabilities into their apps, business systems, and products. ArcGIS Platform gives developers direct access to Esri's powerful location services using the APIs and web frameworks of their choice. "ArcGIS Platform lets users build their own products or integrate Esri services into existing software," said Jack Dangermond, Esri founder and president. "This PaaS makes it easier for software developers to access geospatial technology." "With the release of ArcGIS Platform, developers now have access to professional-grade content and capabilities they can readily plug into their apps, allowing them to stay on budget while delivering enormous value by reducing time to market," said David Cardella, Esri product manager for developer technologies. Scaling with developers and their apps, ArcGIS Platform lets cu

ONWARD Announces Publication in Nature Demonstrating Blood Pressure Stabilization in People with Spinal Cord Injury27.1.2021 17:00:00 CETPress release

ONWARD today announced the publication of a study in the journal, Nature, which found targeted electrical spinal cord stimulation stabilizes blood pressure in people with spinal cord injury (SCI). “A serious and underrecognized result of spinal cord injury is unstable blood pressure, which can have devastating consequences that reduce quality of life and are life threatening. Unfortunately, there are no effective therapies for unstable blood pressure after spinal cord injury,” said Dr. Aaron Phillips, PhD, a member of the Hotchkiss Brain Institute and Libin Cardiovascular Institute at the Cumming School of Medicine (CSM) and co-lead author of the study. “We created the first platform to understand the mechanisms underlying blood pressure instability after spinal cord injury, which allowed us to develop a new cutting-edge solution.” Loss of movement and sensation are the most commonly known impacts of spinal cord injury, but SCI is also frequently accompanied by other effects that chall

Xsolla Establishes New Games Industry Collective, Xsolla Diamond Club27.1.2021 16:32:00 CETPress release

Xsolla, the game commerce company powered by Transaction Engine and Business Engine to help developers and publishers market, sell, connect and optimize their games globally, is now accepting new members to the Xsolla Diamond Club, a professional community of like-minded video game developers and publishers looking to build successful businesses who can connect, learn proven methods and solve shared challenges. Membership to the collective is open to Xsolla clients and potential new partners. Diamond Club members can collaboratively tackle problems around funding, launching, distribution and monetization. To welcome new members, Xsolla is providing free tickets to upcoming sponsored virtual trade shows in 2021. Prospective members can apply to select the event that they would like to attend. After attending their first show, members will also have the benefit of purchasing discounted tickets to 40+ other future events in 2021, including: Taipei Game Show – January 28-31 Pocket Gamer –

C3 AI Reinvents No Code AI with the Introduction of C3 AI Ex Machina27.1.2021 15:00:00 CETPress release

C3 AI (NYSE: AI), the world’s leading provider of enterprise AI software, today announced the general availability of C3 AI® Ex Machina, a next-generation predictive analytics application that empowers anyone to develop, scale, and produce AI-based insights without writing code. Analysts, operators, and subject matter experts across all industries and business functions are increasingly required to develop predictive and prescriptive insights compiled from vast and disparate datasets. While there are many no-code tools available that lower the barrier for users to build ML models and perform data analysis, none provide end-to-end capabilities that enable them to capture and process the volume and variety of data required, automatically generate interpretable AI models, and productize, deploy, and scale the results across their company. Current predictive analytics tools are typically complicated to use and limit the ability of their insights to drive real business outcomes. C3 AI Ex Ma

Philip Morris International Named to the 2021 Bloomberg Gender-Equality Index, Recognizing Company’s Commitment to Advancing Gender Equity27.1.2021 14:18:00 CETPress release

Philip Morris International Inc. (PMI) (NYSE: PM) has today been added to the 2021 Bloomberg Gender-Equality Index (GEI) for its transparency in gender reporting and advancing women’s equity. This recognition underscores PMI’s work to progress gender equity in the workplace and to ensure equal opportunities for all employees. “I am delighted that PMI has been named to the 2021 Bloomberg Gender-Equality Index for our focus on advancing gender equity,” said Silke Muenster, Chief Diversity Officer at PMI. “We count on inclusion to better our organization and believe everyone has an important role to play in making PMI a more inclusive and diverse employer. From striving to improve our gender balance at all levels to maintaining our global leadership on equal pay, our efforts are not only an essential part of being a responsible corporate citizen and contributing to our shared global sustainability goals but also crucial to our progress toward delivering a smoke-free future.” The Bloomberg

Coty Announces Consolidation of Fragrance Manufacturing Operations with Intended Closure of Site in Cologne, Germany27.1.2021 14:10:00 CETPress release

Coty Inc. (NYSE: COTY), one of the world’s leading beauty companies today announced the planned closure of its manufacturing site in Cologne, Germany. The move comes as Coty consolidates global fragrance operations. The Cologne site currently employs approximately 300 people and produces a range of fragrance products. The closure, which will occur in stages, will be preceded by the completion of all appropriate legal processes and is expected to be completed by Summer 2022. Richard Jones, Chief Global Supply Chain and R&D Officer at Coty, said: “We have taken this difficult decision to consolidate our fragrance manufacturing capacity in order to increase the efficiency of our operations. Coty is the world’s leader in fragrance, but our network has been operating over-capacity in recent years and the considerable impact of COVID-19 has accelerated the need to take action. This move will address the imbalance to increase our competitiveness and ensure we fully leverage our scale and rema

UnitedLex Integrates Microsoft Cloud to Globally Scale Digital Transformation of Legal Services27.1.2021 14:00:00 CETPress release

UnitedLex, a leading technology and legal services company, has integrated Microsoft Cloud services to globally scale UnitedLex Vantage, a holistic, turnkey technology platform built to revolutionize the customer experience and transform the legal function into a first-class digital citizen. UnitedLex has integrated Microsoft solutions into its software portfolio since 2008 and has deep experience working closely with Microsoft. UnitedLex Vantage delivers a flexible, secure, and scalable platform, powering all enterprise legal workflows. Vantage comes with a vastly reduced implementation time (a matter of days versus months), a 20 percent increase in work efficiency, significant cost savings across overall legal and IT spend, and most crucially: new revenue opportunities for the business. UnitedLex Chief Technology Officer Sean Jennings said, “We are pleased to deepen our longstanding relationship with Microsoft. The Vantage platform represents a substantial investment for UnitedLex to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom